A9730
Adefovir dipivoxil
别名:
9-(2[bis(Pivaloyloxymethoxy)phosphorylmethoxy]ethyl)adenine
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H32N5O8P
化学文摘社编号:
分子量:
501.47
NACRES:
NA.76
PubChem Substance ID:
UNSPSC Code:
51102829
MDL number:
InChI key
WOZSCQDILHKSGG-UHFFFAOYSA-N
SMILES string
CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C
InChI
1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)
biological source
synthetic
assay
≥98% (HPLC)
form
powder
solubility
ethanol: 50 mg/mL
antibiotic activity spectrum
viruses
mode of action
enzyme | inhibits
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Adefovir is an antiviral acyclic nucleoside phosphonate (ANP) analog that works by blocking reverse transcriptase. It is an inhibitor of duck hepatitis B virus (DHBV) replication that inhibits covalently closed circular DNA (CCC DNA) amplification. Cytotxicity is induced by Human Renal Organic Anion Transporter 1 (hOAT1). Adefovir is an Inhibitor of edema factor (EF)-induced cAMP accumulation and changes in cytokine production in mouse primary macrophages .
Other Notes
Keep container tightly closed in a dry and well-ventilated place.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.
Yuequan Shen, Natalia L. Zhukovskaya, et. Al
Proceedings of the National Academy of Sciences of the USA, 101, 3234-3247 (2004)
Andrea Puhar et al.
PloS one, 3(10), e3564-e3564 (2008-10-30)
Anthrax edema toxin (EdTx) is an adenylate cyclase which operates in the perinuclear region of host cells. However, the action of EdTx is poorly understood, especially at molecular level. The ability of EdTx to modulate cAMP-dependent signaling was studied in
Helen Cooksley et al.
Antimicrobial agents and chemotherapy, 52(1), 312-320 (2007-11-07)
Weak T-cell reactivity to hepatitis B virus (HBV) is thought to be the dominant cause for chronic HBV infection. Treatment with adefovir dipivoxil (ADV) increases the rate of HBV e antigen (HBeAg) loss; however, the immune mechanisms associated with this
F Stelma et al.
Journal of viral hepatitis, 24(12), 1107-1113 (2017-06-21)
Combining peginterferon-alfa-2a (pegIFN) with a nucleotide analogue can result in higher rates of HBsAg loss than either therapy given alone. Here, we investigated the durability of the response to combination therapy in chronic hepatitis B (CHB) patients after 5 years of
Baek Gyu Jun et al.
PloS one, 13(7), e0201316-e0201316 (2018-07-31)
Convincing data that support routine use of preventive therapy against hepatitis B virus (HBV) reactivation in radiotherapy (RT) for hepatocellular carcinoma (HCC) are lacking. The aim of this study was to investigate the incidence, clinical significance, and risk factors of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持